Our goal is to efficiently commercialize novel compound drugs engineered to enhance our brain’s neuroplasticity.
We have assembled an experienced team of scientists, pharmacologists, clinicians, and businesspeople with decades of experience in the neurosciences. We have designed and are executing a capital efficient, go-to-market strategy for our first drug, NIV-001, which we expect to greatly improve the effectiveness of chronic stroke rehabilitation.
Co-Founder & CEO
Co-Founder & Chief Medical Officer
Co-Founder & IP Counsel
VP Drug Development
VP Clinical Studies